Pharvaris (PHVS)
(Delayed Data from NSDQ)
$18.77 USD
+0.53 (2.91%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $18.56 -0.21 (-1.12%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PHVS 18.77 +0.53(2.91%)
Will PHVS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PHVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHVS
Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal
Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program
PHVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
Wall Street Analysts Predict an 88.24% Upside in Pharvaris N.V. (PHVS): Here's What You Should Know
Other News for PHVS
Pharvaris Shareholders Approve Key Resolutions
Morgan Stanley Remains a Buy on Pharvaris (PHVS)
Pharvaris Announces Annual Meeting of Shareholders
Pharvaris Schedules 2024 Shareholder Meeting
Analysts Offer Insights on Healthcare Companies: OrthoPediatrics (KIDS), Pharvaris (PHVS) and Cue Biopharma (CUE)